Herpesvirus saimiri (HVS) 
Introduction
The fundamental basis of gene therapy involves the introduction of a therapeutic gene, which will cure or slow the progression of a disease. Current viral vectors do not possess the full complement of properties that are generally believed necessary in an ideal gene delivery system. Retroviral vectors are the most widely used vehicles for gene therapy applications, as they have the ability to stably integrate into the host genome providing longterm gene expression. 1 However, random integration may result in insertional mutagenesis or reduced transgene expression. 2 Adenoviruses are capable of infecting non-dividing and dividing cells with high efficiency. 3 However, the duration of expression can be limited due to humoral immune responses induced by the infection. 4 Adeno-associated vectors are nonpathogenic and nonimmunogenic, but are limited by the packaging capacity for foreign DNA, approximately 4.5 kb. 5 Therefore, alongside attempts to improve current gene delivery vectors, the identification and evaluation of new viral vectors is crucial to the long-term success of gene therapy.
Herpesviruses are large DNA viruses, with genomes ranging in size between 100 and 250 kb. They are divided into alpha, beta and gamma subgroups on the basis of their biological and genetic properties. 6 As a family, their advantages as gene therapy vectors relate to an ability to package large DNA insertions and establish lifelong latent infections in which the genomic material exists as a stable episome. To date, research has focussed on the use of herpes simplex virus (HSV) vectors for gene transfer to the nervous system. 7 deletions within one or more of the immediate-early genes have been shown to infect and remain latent in neurons with limited toxicity. 9, 10 Furthermore, long-term transgene expression has been achieved using the latency-associated transcript regulatory regions. 11, 12 To further minimise HSV toxicity, HSV amplicons have been developed. These consist of a plasmid bearing the HSV lytic replication origin and terminal packaging signals which allow it to be amplified and packaged into infectious HSV particles in the presence of helper-virus. [13] [14] [15] As such they constitute a cloning vehicle which can efficiently carry genetic information between prokaryotic and eukaryotic cells. Amplicons retain many of the characteristics of standard HSV vectors. However, amplicon stocks tend to have lower titres. 16 A problem shared by all HSV-based vector systems is the fact that the genome has no 'latent origin' of DNA replication, meaning that a state of episomal maintenance cannot be established in dividing cells. Epstein-Barr virus (EBV), a member of the gamma-herpesviruses, is capable of establishing a latent state in dividing cells where the viral episome replicates co-ordinately with cell division and is inherited by progeny cells. 17 Such a vector derived from EBV may be suitable for gene therapy applications. 18 However, EBV is associated with a number of human malignancies and lymphoproliferative disorders, necessitating extensive modification of the virus genome to eliminate those genes involved in transformation. 17 We are currently assessing the potential of alternative herpesviruses as possible gene therapy vectors. Herpesvirus saimiri (HVS) is a gamma-2 herpesvirus of squirrel monkeys, which persistently infects its natural host without causing any obvious disease. 19 Although HVS infection of other species of New World primates can result in lymphoproliferative diseases, this can be completely eliminated by deletion of the transforming genes, STP and Tip. 20 The vectors utilised herein possess these deletions and as such are thought to be incapable of transforming any cell type. We and others have demonstrated that HVS is capable of infecting a range of human cell lines with high efficiencies. Moreover, the HVS viral genome is able to establish a latent episomal state within human carcinoma cell types and segregate to progeny upon cell division. [21] [22] [23] This allows the virus to stably transduce a dividing cell population and provide transgene expression for an extended period of time. 24 The aim of this study was to examine the in vivo characteristics of HVS to allow a full appraisal of its potential as a gene therapy vector. To this end, we have used human colorectal and pancreatic carcinoma cell lines stably infected with HVS, to induce tumour xenografts in nude mice. Our data demonstrate that HVSbased vectors persist as circular nonintegrated episomes in vivo, which provide sustained transgene expression with no evidence of viral spread, promoter silencing or cytopathic effects.
Results

Herpesvirus saimiri does not affect cell growth in vitro
We have previously constructed a recombinant HVS, HVS-GFP, expressing the green fluorescent protein (GFP) and the neomycin resistance genes under the control of the IE CMV and SV40 promoters, respectively. 25 In order to generate colorectal and pancreatic carcinoma cell lines which contained HVS as a nonintegrated circular episome, SW480 and MiaPaCa cells were infected with HVS-GFP and cultured in the presence of geneticin. After 2 weeks, only those cells which had been successfully transduced remained viable, with 100% exhibiting the GFP phenotype when analysed by fluorescence microscopy (data not shown). The cells continued to grow and express the transgene in the presence of selection for over 12 months, suggesting that the infection in these cell types is highly stable. To determine whether stable transduction of cells with HVS affected cell growth, the growth rates of wild-type (wt) SW480 and MiaPaCa cells and stably transduced SW480 HVS-GFP and MiaPaCa HVS-GFP cells were compared in vitro over a growth period of 5 days. No significant difference in the doubling time of the cell populations was observed between wt SW480 (23 ± 5 h, n = 3) and SW480 HVS-GFP cells (21 ± 4 h, n = 3, P Ͻ 0.05) or wt MiaPaCa (22 ± 2 h, n = 3) and MiaPaCa HVS-GFP cells (20 ± 1 h, n = 3, P Ͻ 0.05, two-tailed, Student's t test) (Figure 1 ). These data suggest that the maintenance of the HVS episome does not disrupt the growth machinery of human cancer cells in vitro. This is consistent with previous results demonstrating that HVS does not affect growth of human lung carcinoma cells or the growth and differentiation of mouse embryonic stem cells.
24-27
The HVS genome persists in human tumour cell xenografts We have previously shown that the HVS genome exists as a nonintegrated, circular, latent episome in a persistently infected human lung carcinoma cell line. 24 To elucidate whether HVS could be latently maintained in an in vivo environment or if viral reactivation occurred leading to the spread of the virus to other host tissues, tumour xenografts were induced in nude mice. Wild-type or HVS-infected SW480 or MiaPaCa carcinoma cells (10 7 /animal) were injected into the right flank of Balb/C nude mice and tumour xenografts were allowed to grow to a size of approximately 10 × 10 mm. DNA and RNA were then extracted from the tumour, brain, heart, lungs, liver, kidney, spleen and colon of each animal for analysis.
To verify the presence of the HVS genome in the tumour xenografts and detect any spread to other major organs, PCR amplification was utilised. Specific amplification of open reading frame (ORF) 57, an immediateearly gene involved in viral replication, 28, 29 and ORF 73, a gene latently expressed in human carcinoma cell lines, 24 was performed using DNA isolated from the tumour and tissue samples. In addition, as a suitable control, GAPDH DNA was detected in all samples indicating that sufficient amounts of DNA had been extracted from each tissue. ORF57 and ORF73 viral DNA were readily detected in tumour xenografts generated from SW480 HVS-GFP, but not in any other host tissues ( Figure 2b ). As expected viral DNA was not detected in tumour xenografts of wt SW480 cells (Figure 2a) . Similar results were observed in mice bearing MiaPaCa HVS-GFP xenografts (data not shown). To confirm this result, the PCR samples were Southern blotted and probed with radiolabelled probes directed against viral DNA (ORF 73) and GAPDH ( Figure 2e ). The more sensitive method of Southern blotting did not detect any viral DNA present in host tissues. These results indicate that the virus can persist within the human carcinoma cell xenografts without detectable spread to surrounding tissues.
To determine whether any viral gene expression occurred in tumour xenografts, RT-PCR amplification of ORF57 and ORF73 was performed using RNA isolated from the tumour and tissue samples. As a control,
Figure 2 HVS DNA persists in SW480 human tumour cell xenografts. The presence of HVS DNA was identified by the PCR amplification of ORFs 73 (i) and 57 (ii) from DNA extracted from tumour and tissue samples of mice bearing (a) wt SW480 and (b) SW480 HVS-GFP infected cells. GAPDH DNA (iii) was detected in all samples indicating that sufficient amounts of DNA had been extracted from each tissue. The presence of HVS latent and lytic gene expression was identified by RT-PCR amplification of ORFs 73 (i) and 57 (ii) from RNA extracted from tumour and tissue samples of mice bearing (c) wt SW480 and (d) SW480 HVS-GFP infected cells. GAPDH RNA (iii) was detected in all samples indicating that sufficient amounts of RNA had been extracted from each tissue. These results are representative of four independent assays. (e) Southern blot analysis, probed with ORF 73 (i) and GAPDH (ii), of HVS DNA PCR amplified from tumour and tissue samples of mice bearing SW480 HVS-GFP infected cells.
GAPDH expression was detected in all samples. ORF73 RNA were detected in SW480 HVS-GFP xenografts, but this transcript was absent in other host tissues ( Figure  2d ). This indicates latent gene expression within the tumour xenografts, as previously described for other carcinoma cell lines in vitro. 24 Similar results were observed in mice bearing MiaPaCa HVS-GFP xenografts (data not shown). RT-PCR analysis also identified low levels of ORF57 expression in SW480 HVS-GFP (Figure 2d ) and MiaPaCa HVS-GFP (data not shown) tumour xenografts but not in any host tissues. This suggests that there may be low levels of lytic gene expression within these tumour xenografts. At present, however, the absence of viral DNA and RNA in host mouse tissues suggests that infectious virus is either not produced or if produced does not spread from the tumour xenograft site. The presence of lytic gene expression is not surprising, as we have previously observed a very low level of spontaneous replication in stably transduced lung carcinoma cell lines in vitro. 24 The possibility of virus production cannot be ruled out, and therefore necessitates the development of disabled HVS-based vectors for potential future clinical applications.
HVS is maintained as a circular episome in vivo
As previously mentioned, the HVS genome persists as a circular episome in human carcinoma cell lines in vitro. [21] [22] [23] [24] To verify the existence of HVS genomes in a circular, nonintegrated episomal form in vivo, wild-type or HVS-infected SW480 and MiaPaCa xenografts were analysed by Gardella gel electrophoresis and Southern blot analysis, as previously described. 30, 31 A HVS-transformed T cell line from cottontop tamarin monkeys, 32, 33 which contains HVS as a circular nonintegrated episome was also analysed as a suitable control. Results show a band corresponding to episomal HVS DNA present in SW480 HVS-GFP and MiaPaCa HVS-GFP tumour xenografts that was not present in tumour xenografts generated from the corresponding wt cells (Figure 3) . However, closer inspection of the Southern blot did identify a number of episomal bands as previously observed. 24 To determine whether this was the same mixed population of episomal forms or whether rearrangement/deletions of the episome had occurred in vivo, the blot was reprobed with a variety of genomic fragments including KpnE and EcoC fragments encompassing the left-hand end of the viral genome. Similar results were observed with these probes suggesting that the episomes are of the same population and are not undergoing spontaneous rearrangements or deletions (data not shown). Thus, this in vivo result is in agreement with previous in vitro data, the HVS DNA is not incorporated into the host cell genome following at least 3 months of growth and persists as a circular nonintegrated episome. The HVS episome provides sustained transgene expression in vivo To determine whether HVS episomes allow expression of a transgene in vivo, Western blot analysis was performed on protein extracted from the tumour and tissue samples. GFP expression was only detected in the SW480 HVS-GFP tumour xenografts, consistent with the absence of viral DNA and RNA in any other host mouse tissue (Figure 4) . Similar results were observed in mice bearing MiaPaCa HVS-GFP xenografts (data not shown). As a control, actin expression was detected in all protein samples indicating that sufficient amounts of protein had been extracted from each tissue. This suggests that the HVS episome can provide sustained transgene expression over the course of the 3-month human carcinoma xenograft experiment.
To further visualise the amount of GFP expression throughout the human carcinoma xenograft, the tumours were exposed to light emitted at the excitation wavelength for GFP (488 nm) before removal. This showed widespread and intense GFP fluorescence in SW480 HVS-GFP tumour xenografts, but not in the corresponding wt tumour xenografts ( Figure 5 ). Similar results were observed in mice bearing MiaPaCa HVS-GFP xenografts (data not shown). This result suggests that the HVS episome is segregated efficiently in vivo and maintained
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Figure 4 Transgene expression from the HVS episome in vivo. Protein extracts from tumour and tissue samples from mice bearing (a) wt SW480 and (b) SW480 HVS-GFP infected cells. Protein samples were resolved on a SDS polyacrylamide gel, transferred to nitrocellulose membranes and incubated with a anti-GFP monoclonal antibody (i) or anti-actin antibody (ii), to indicate that sufficient amounts of protein had been extracted from each tissue. These results are representative of three independent assays.
throughout the 3-month period of tumour xenograft growth. Furthermore, little if any silencing of the heterologous IE CMV promoter contained in the HVS episome was observed in these carcinoma cells in vivo.
To confirm that the HVS episome had segregated to each of the tumour cells in the xenograft, cross-sections of tumour xenografts were taken and analysed by fluorescence microscopy. GFP expression was observed in over 90% of the cells throughout the SW480 HVS-GFP tumour xenografts (Figure 6a ). Similar results were observed from the sections of the MiaPaCa HVS-GFP xenograft (data not shown). Furthermore, to verify the presence of the HVS episome in these GFP-expressing cells, immunohistochemistry was performed using an antibody directed to ORF 73, 34 on tumours derived from wt or HVS-infected cells. These results show that ORF 73 expression was detected in over 90% of the cells throughout the SW480 HVS-GFP tumour section, but was not detected in control tumours (Figure 6b ). This result confirms the presence of the HVS genome in virtually all of the cells throughout the xenograft section and suggest that the HVS episome is efficiently segregated in these human carcinoma cells in vivo.
Discussion
Large DNA viruses, such as herpesviruses, have advantages as gene delivery vectors, because of their ability to accommodate large amounts of heterologous DNA into their genome. Furthermore, long-term persistence of the
Figure 5 HVS episomes provide sustained transgene expression in vivo. The amount of GFP expression was analysed from mice bearing wt SW480 (i) and SW480 HVS-GFP (ii) tumours under (a) normal light and (b) light emitted at the excitation wavelength for GFP (488 nm).
Figure 6 Efficient transfer of the HVS episome allows sustained transgene expression. (a) To examine the amount of GFP expressed throughout the wt SW480 (i + ii); SW480 HVS-GFP (iii + iv) tumour xenograft crosssections were analysed under normal light (i + iii) and light emitted at the excitation wavelength for GFP (ii + iv). (b) To confirm the presence of HVS episome in GFP-expressing cells the wt SW480 (i); SW480 HVS-GFP (ii) tumour xenograft cross-sections were analysed by immunohistochemistry for the expression of the HVS ORF 73 protein.
viral genome may help to provide continual foreign gene expression. In this report we have further assessed the potential of the prototype gamma-2 herpesvirus, HVS, as a gene delivery vector. We and others have demonstrated that HVS is capable of infecting a range of human cell lines with high efficiencies. Moreover, the HVS genome is able to establish a latent episomal state within human carcinoma cell types and segregate to progeny upon cell division. [21] [22] [23] [24] This allows the virus to stably transduce a dividing cell population and provide transgene expression for an extended period of time. 24 However, to date these studies have been performed using in vitro assays. Therefore, we have performed an evaluation of the in vivo properties of HVS, with a view to its development as a gene delivery system. We demonstrate that the HVS genome can persist in a tumour xenograft generated from HVS-infected human carcinoma cell lines. The HVS-based vector remained latent throughout the xenograft without spreading to other organs. However, RT-PCR analysis has demonstrated the presence of low levels of lytic gene expression within these tumour xenografts. The absence of viral DNA and RNA in host mouse tissues suggests that infectious virus is not produced by stably transduced cells in vivo or, if produced, infectious virus does not spread from the tumour xenograft site. At present, although we cannot identify viral genomes present in any mouse tissue we cannot rule out the possibility of virus production within the tumour xenograft. Therefore, as a prerequisite for potential future clinical applications, the development of disabled HVSbased vectors is essential. To this end, we have previously identified the two major HVS transcriptional control genes encoded by ORFs 50 and 57 which are required to initiate lytic gene expression. 28, 29, 35 These results suggest that ORFs 50 and 57 are potentially ideal genes to delete in order to produce safe replication-disabled HVSbased vectors.
The long-term persistence of the HVS genome within the tumour xenograft indicates that upon cell division in vivo, the HVS episomal DNA was efficiently replicated and segregated to nearly all daughter cells for at least a 3-month period. This was a relatively surprising result, as a characteristic feature of other herpesvirus episomal systems is the exponential loss of the episome. For example, EBV episomes are lost at a rate of approximately 2-10% per cell generation in the absence of selection. 36 We have previously observed that the HVS episome can similarly be lost upon the removal of selection in vitro, but Southern blot analysis demonstrated over 95% retention of the HVS episome in a persistently infected Jurkat cell line. Therefore, the level of retention appears to compare favourably with EBV-based systems. 26 The level of retention in human tumour cell xenografts appears even higher. Cross-sections of the tumour xenograft demonstrate the presence of the HVS episome and GFP expression in virtually all of the cells, suggesting that the HVS episome is replicated and retained highly efficiently. Due to tumour size constraints, we were unable to determine the ultimate duration of HVS episome persistence in this dividing cell population in vivo. Moreover, at present we have not addressed the humoral and cellular immune responses to HVS-based vectors. Although long-term maintenance and expression was obtained in the immunological incompetent female athymic Balb/C nude mice, we have no indication that these results will be similar in an immunocompetent animal. However, work in this area is ongoing.
The replication and stable maintenance of EBV episomes require only two viral elements; the nuclear protein, EBNA-1 and the latent replication origin, OriP. 37 EBNA-1 governs the segregation of EBV episomes by mediating the attachment of OriP to host cell mitotic chromosomes. 38 At present, the mechanism of HVS episomal maintenance is unknown. However, it has recently been shown that the KSHV ORF 73 protein colocalises with KSHV episomes along mitotic chromosomes and binds KSHV terminal repeat DNA, allowing the persistence of KSHV episomes in dividing cells. 39 Whether the HVS ORF 73 functions in a similar manner is currently being determined.
In summary, HVS have a number of features that are promising for vector development. First, it has the ability to accommodate large arrays of heterologous DNA. Second, HVS can infect a wide variety of human cells, including carcinoma cells and cells of the haemopoietic lineage. 21, 22, 25, 26 Finally, the viral genome persists as a high copy number episome, and therefore precludes problems arising from chromosomal integration, such as insertional mutagenesis and silencing from genomic positioning effects. Therefore, HVS has the characteristics of an efficiently delivered artificial chromosome. A similar gene delivery system based on Epstein-Barr virus has recently been shown to accommodate 100 kb of human sequences. 40, 41 These features may have several applications for the treatment of human diseases. For example, the large packaging capability allows the incorporation of multiple therapeutic genes for the treatment of polygenic diseases such as cancer. Furthermore, the high packaging capability would allow the incorporation of complete eukaryotic cis-regulatory elements to provide the correct level and tissue-specific expression of a therapeutic gene. In addition, HVS-based vectors have been shown to be efficient vectors for transduction and long-term expression in human T lymphocytes. Therefore, HVSbased vectors are currently being developed for T cellmediated immunotherapy of resistant residual leukaemia. 32 However, therapeutic applications will require the clarification of a number of biosafety aspects. Although, HVS infects its natural host, the squirrel monkey, without causing any obvious disease, infection of other species of New World primates with HVS can result in lymphoproliferative diseases. 19 This can be eliminated completely by deletion of the saimiri-transforming protein (STP). 20 The vectors utilised herein possess these deletions and as such are incapable of transforming any cell type. Interestingly, these results also demonstrate that the elements required for episomal maintenance, albeit in human carcinoma cells, are still functional in these STP-deleted viruses. Additional safety mechanisms Gene Therapy should include the incorporation of a suicide gene for active elimination of the vector if required. In addition, replication-deficient and packaging cell-dependent viruses are necessary to eliminate any virus replication.
Materials and methods
Cell culture SW480 human colon adenocarcinoma cells were routinely grown in RPMI 1640 medium (Life Technologies, Paisley, UK) supplemented with 10% (v/v) foetal calf serum (FCS). MiaPaCa human pancreatic carcinoma cells were maintained in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% FCS. All media contained penicillin (100 U/ml) and streptomycin (100 g/ml) (Life Technologies). SW480 and MiaPaCa cells were stably transduced with HVS-GFP, as previously described. [24] [25] [26] [27] Briefly, 10 6 cells were infected with HVS-GFP at a multiplicity of infection of 1 and cultured in the presence of 600 g/ml of Genetecin (Life Technologies). HVS-transformed T cells from cottontop tamarin monkeys, B133 cells 32, 33 were grown in RPMI 1640 medium supplemented with 10% FCS and interleukin-2 (20 U/ml).
The cell population doubling time was determined by seeding 2 × 10 4 cells per well of a 24-well plate. Every 24 h cells were trypsinised and counted using a haemocytometer. The doubling times (cell growth rate) were calculated for each cell line using the equation: doubling time = 0.69/K, where K = exponential rate constant.
In vivo analysis
Female athymic Balb/C nude mice (8-10 weeks old; Harlan, UK) were maintained and handled in isolators under specific pathogen-free conditions. Mice were randomised into groups of four and wt SW480, SW480 HVS-GFP, wt MiaPaCa, and MiaPaCa HVS-GFP xenografts were induced by subcutaneous injection of 1 × 10 7 cells in 50 l of PBS into the right flank. Human tumour xenografts were allowed to grow to a size of 10 × 10 mm after which mice were killed. The tumour, brain, liver, lung, kidney, heart, spleen and colon were removed, snap frozen in liquid nitrogen and stored at -80°C before RNA, DNA and protein analysis.
PCR analysis
Tissue samples were homogenised in 10 volumes of Trizol (Life Technologies). DNA and RNA were then extracted as described by the manufacturer. The HVS ORFs 57 and 73, mGAPDH and hGAPDH were PCR amplified with the following set of primers: ORF57f (5Ј-GAA ACA ATT GCT AGT GCT AAT CTT TGC-3Ј); ORF57r (5Ј-TGG AGA CTT GTT TAA GAA CTG TGT GAG AC-3Ј); ORF73f (5Ј-CGC GGA TCC ATG GAA GCA GGA CCA AGT ACT CCA-3Ј); ORF73r (5Ј-CCG CTC GAG CCT TCT ATA GGC AGG CTT TTG CT-3Ј); mGAPDHf (5Ј-GGT CAT CAT CTC CGC CCC TTC TGC-3Ј); mGAPDHr (5Ј-GAG TGG GAG TTG CTG TTG AAG TCG-3Ј); hGAPDHf (5Ј-CCA CCC ATG GCA AAT TCC ATG GCA-3Ј) and hGAPDHr (5Ј-TCT AGA CGG CAG GTC AGG TCC ACC-3Ј). The reaction, 30 cycles (1 min, 92°C, 1 min 58°C, 1 min 72°C) was performed with 4 units of Taq Polymerase (Promega, Madison, WI, USA). RT-PCR analysis was performed using the Superscript
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Preamplification system (Life Technologies) utilising the same set of primers as above.
Gardella gel electrophoresis and Southern blot analysis
Tumour tissue was cut into pieces of approximately 1-2 mm 3 , incubated with a solution of 150 U/ml collagenase/dispase (Sigma, St Louis, MO, USA) in RPMI 1640 medium (SW480 xenograft) or DMEM (MiaPaCa xenograft) containing 10% FCS for 4 h at 37°C and then dissociated by passing through a 23-gauge needle. Episomal DNA molecules were detected using the Gardella technique, as previously described. 30, 31 Horizontal gels were prepared in two steps. Initially a 0.75% agarose gel in Tris-borate-EDTA buffer was poured. Once solidified, 5 cm of the gel was removed and replaced with 0.8% agarose containing 2% sodium dodecyl sulphate and 1 mg/ml of self-digested pronase (Sigma). Tissue and cell pellets were resuspended in sample buffer (15% Ficoll, 0.01% bromophenol blue) and electrophoresed at 4°C for 2 h at 40 V and then 18 h at 160 V. DNA was hybridized with a 32 P-radiolabelled random-primed probe specific for the KpnE fragment of the HVS genome, using the Megaprime kit (Amersham, Buckinghamshire, UK), as described by the manufacturer.
Immunoblot analysis
Tumour and tissue samples were homogenised in five volumes of suspension buffer (0.1 m NaCl, 10 mm Tris.HCl (pH 8.0), 1 mm EDTA and 0.1 mg/ml AEBSF protease inhibitor (Roche, East Sussex, UK)). Protein extracts were resolved on a 10% SDS polyacrylamide gel, then soaked for 10 min in transfer buffer (25 mm Tris, 192 mm glycine, 20% methanol (v:v), and 0.1% SDS). The proteins were transferred to nitrocellulose membranes by electroblotting for 3 h at 250 mA. After transfer, the membranes were soaked in PBS and blocked by preincubation with 2% (w/v) non-fat milk powder for 2 h at 37°C. Membranes were incubated with a 1/1000 dilution of the anti-GFP monoclonal antibody (Clontech, Palo Alto, CA, USA) or anti-actin antibody (Sigma), washed with PBS and incubated for 1 h at 37°C with a 1/1000 dilution of anti-mouse immunoglobulin conjugated with horseradish peroxidase (Dako, Cambridge, UK) in blocking buffer. After five washes with PBS the nitrocellulose membranes were developed using ECL (Pierce, Cheshire, UK) according to the manufacturer's directions.
Photography
Mice were photographed under normal light with a yellow Whatman 12 filter (Kodak, Hertfordshire, UK) to eliminate any contaminating blue light. Blue light was used at a wavelength of 488 nm to excite GFP (emission at 507 nm) and the camera film exposed for 2 min.
Immunohistochemistry
Tumour specimens were embedded in Cryo-M-bed (Bright Instruments, UK), frozen on dry ice and stored at -80°C. Frozen samples (10 m) were sectioned using a Leica CM3050 cryostat and either observed for GFP expression using a Zeiss Axiovert 135TV inverted fluorescence microscope with a Neofluar 40× oil immersion or analysed for ORF 73 expression. Frozen cyrosections were fixed using acetone/methanol (1:1), incubated in hydrogen peroxide/methanol (0.06%) and blocked by preincubation with 20% normal swine serum for 1 h. A 1:50 dilution of anti-ORF 73 polyclonal antibody 34 was layered over the section and incubated for 1 h. After washing with PBS, the sections were incubated for 30 min with 1:500 dilution of swine-anti-rabbit secondary antibody conjugated to biotin (Dako), washed and then incubated in ABComplex/HRP reagent (Dako) for 30 min, according to the manufacturer's specifications. Finally, the sections were incubated in diaminobenzidine, cleared in ethanol and xylene, and mounted for light microscopy viewing.
